Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase III Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. announced that the last participant has completed the GEM-3 study, Krystal’s pivotal Phase III clinical trial evaluating investigational beremagene geperpavec (B-VEC) as a topical gene therapy for the treatment of dystrophic epidermolysis bullosa.